We are committed to finding a cure for WM.

Did you know?

 

Welcome to the Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC)

If you have been diagnosed with Waldenstrom’s Macroglobulinemia (WM) or care for someone who has, welcome to the WMFC family of WM patients, caregivers, friends and relatives. We are a community providing support, research and information on WM.

Sign up for our newsletter below to receive updated information.

 

Information for the newly diagnosed

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

Source: https://www.cancertherapyadvisor.com/hematologic-cancers/waldenstrom-macroglobulinemia-zanubrutinib-new-trial-treatment/article/801383/ A head-to-head, open-label, multicenter, phase 3 clinical trial comparing the efficacy and safety of zanubrutinib (BGB-3111) with ibrutinib in patients with Waldenström macroglobulinemia (WM) is underway (ClinicalTrials.org Identifier: NCT03053440).1 The study also Read More

FDA Approves First Chemotherapy-Free Treatment for Waldenström’s Macroglobulinemia

This morning, August 27, 2018, the US Food and Drug Administration (FDA) approved ibrutinib (IMBRUVICA, AbbVie) in combination with rituximab (RITUXAN) for the treatment of Waldenström’s macroglobulinemia. This combination is Read More

Expert Highlights Potential of Zanubrutinib in Waldenstrom Macroglobulinemia

Zanubrutinib (BGB-3111), an investigational small molecule inhibitor of BTK, showed promising activity in patients with Waldenström macroglobulinemia (WM), according to updated results presented at the 2018 European Hematology Association Congress. Read More

Subscribe to our newsletter